Clinical Research Directory

Inclusion Criteria: 1. Phologically confirmed colorectal adenocarcinoma 2. Treated by oxaliplatin and irinotecan and discontinued due to progression or intolerable drug toxicity 3. ECOG 0-2 4. Predicted survival more than 3 months 5. Estimated by investigators that the main organ function is enough good to tolerate the next treatment plan. 6. Sign informed consent. 7. Agree to receive survival follow-up Exclusion Criteria: 1. Previously exposed to regorafenib, furoquintinib, TAS-102, PD-1 inhibitors, or targeted drugs or immunotherapy for HER2 amplification, BRAF V600E mutation, and NTRK gene fusion. 2. Previously rechallenged or retreated by oxaliplatin or irinotecan after progression from chemotherapy regimens including oxaliplatin and irinotecan. 3. Participate in another interventional clinical study at the same time, unless in the follow-up stage of intervention study. 4. Proposed to use a treatment regimen containing regorafenib, furquintinib, and trifluridine, but has any problems obstacling oral drugs, such as inability to swallow, chronic diarrhea and intestinal obstruction et al. 5. Disagree to take contraceptive measures during the study treatment period or within 6 months after the end of the study treatment period. 6. Has other primary malignant tumor history, unless non-melanoma skin cancer or lentigo maligna or carcinoma in situ with sufficient treatment and no disease recurrence. 7. Has the history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation. 8. Has concomitant diseases that seriously endanger patient safety or affect patient completion of the study. 9. Has other problems that is not suitable for clinical research.